Circulating dickkopf-1 in diabetes mellitus: Association with platelet activation and effects of improved metabolic control and low-dose aspirin

Journal of the American Heart Association

Volumn 3, Issue 4, 2014, Pages

  Lattanzio, Stefano ^a   Santilli, Francesca ^a   Liani, Rossella ^a   Vazzana, Natale ^a   Ueland, Thor ^b   Di Fulvio, Patrizia ^a   Formoso, Gloria ^a   Consoli, Agostino ^a   Aukrust, Pål ^b   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Diabetes mellitus; DKK 1; Endothelial dysfunction; Inflammation; Platelet activation; Platelet derived factor

Indexed keywords

11 OXOTHROMBOXANE B2; ACARBOSE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD40 LIGAND; DICKKOPF 1 PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INCRETIN; INSULIN; METFORMIN; N(G),N(G) DIMETHYLARGININE; ORAL ANTIDIABETIC AGENT; POLYUNSATURATED FATTY ACID; PROTON PUMP INHIBITOR; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; 11-DEHYDRO-THROMBOXANE B2; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ARGININE; BIOLOGICAL MARKER; DKK1 PROTEIN, HUMAN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; N,N-DIMETHYLARGININE; SIGNAL PEPTIDE; THROMBOXANE B2;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DICKKOPF 1 PROTEIN BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; IN VIVO STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; THROMBOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CARDIOVASCULAR DISEASES; CASE CONTROL STUDY; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; URINE; WNT SIGNALING PATHWAY;

AGED; ARGININE; ASPIRIN; BIOMARKERS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CD40 LIGAND; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; WNT SIGNALING PATHWAY;

EID: 84929141889     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001000     Document Type: Article

References (34)

1. Daví G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-2494.
2. Vazzana N, Ranalli P, Cuccurullo C, Daví G. Diabetes mellitus and thrombosis. Thromb Res. 2012;129:371-377.
3. Aukrust P, Müller F, Ueland T, Berget T, Aaser E, Brunsvig A, Solum NO, Forfang K, Frøland SS, Gullestad L. Enhanced levels of soluble and membranebound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614-620.
4. Ferroni P, Riondino S, Vazzana N, Santoro N, Guadagni F, Daví G. Biomarkers of platelet activation in acute coronary syndromes. Thromb Haemost. 2012;108:1109-1123.
5. Santilli F, Paloscia L, Liani R, Di Marco M, Lattanzio S, La Barba S, Pascale S, Mascellanti M, Davi G. Circulating MRP 8/14 is related to thromboxanedependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. JAHA. 2014.
6. Santilli F, Daví G, Consoli A, Cipollone F, Mezzetti A, Falco A, Taraborelli T, Devangelio E, Ciabattoni G, Basili S, Patrono C. Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:391-397.
7. Chien AJ, Moon RT. WNTS and WNT receptors as therapeutic tools and targets in human disease processes. Front Biosci. 2011;12:448-457.
8. Zimmerman ZF, Moon RT, Chien AJ. Targeting Wnt pathways in disease. Cold Spring Harb Perspect Biol. 2012;4:a008086.
9. Christman MA II, Goetz DJ, Dickerson E, McCall KD, Lewis CJ, Benencia F, Silver MJ, Kohn LD, Malgor R. Wnt5a is expressed in murine and human atherosclerotic lesions. Am J Physiol Heart Circ Physiol. 2008;294:H2864-H2870.
10. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210-1220.
11. Jin T. The WNT signalling pathway and diabetes mellitus. Diabetologia. 2008;51:1771-1780.
12. Seifert-Held T, Pekar T, Gattringer T, Simmet NE, Scharnagl H, Stojakovic T, Fazekas F, Storch MK. Circulating Dickkopf-1 in acute ischemic stroke and clinically stable cerebrovascular disease. Atherosclerosis. 2011;218:233-237.
13. Kim KI, Park KU, Chun EJ, Choi SI, Cho YS, Youn TJ, Cho GY, Chae IH, Song J, Choi DJ, Kim CH. A novel biomarker of coronary atherosclerosis: serum DKK1 concentration correlates with coronary artery calcification and atherosclerotic plaques. J Korean Med Sci. 2011;26:1178-1184.
14. Ueland T, Otterdal K, Lekva T, Halvorsen B, Gabrielsen A, Sandberg WJ, Paulsson-Berne G, Pedersen TM, Folkersen L, Gullestad L, Oie E, Hansson GK, Aukrust P. Dickkopf-1 enhances inflammatory interactions between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1228-1234.
15. Voorzanger-Rousselot N, Goehrig D, Facon T, Clézardin P, Garnero P. Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. Br J Haematol. 2009;145:264-266.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29:S43-S48.
17. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Circulation. 2010;121:2694-2701.
18. Lorenzo C, Williams K, Hunt KJ, Haffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30:8-13.
19. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOPNIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072-2077.
20. Santilli F, Formoso G, Sbraccia P, Averna M, Miccoli R, Di Fulvio P, Ganci A, Pulizzi N, Lattanzio S, Ciabattoni G, Consoli A, Lauro R, Patrono C, Daví G. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost. 2010;8:828-837.
21. Khuu HM, Robinson CA, Goolsby K, Hardy RW, Konrad RJ. Evaluation of a fully automated high-performance liquid chromatography assay for hemoglobin A1c. Arch Pathol Lab Med. 1999;123:763-767.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
23. Daví G, Averna M, Catalano I, Barbagallo C, Ganci A, Notarbartolo A, Ciabattoni G, Patrono C. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 1992;85:1792-1798.
24. 2 in man. Biochim Biophys Acta. 1989;992:66-70.
25. Smadja DM, d'Audigier C, Weiswald LB, Badoual C, Dangles-Marie V, Mauge L, Evrard S, Laurendeau I, Lallemand F, Germain S, Grelac F, Dizier B, Vidaud M, Biéche I, Gaussem P. The Wnt antagonist Dickkopf-1 increases endothelial progenitor cell angiogenic potential. Arterioscler Thromb Vasc Biol. 2010;30:2544-2552.
26. Wang L, Hu XB, Zhang W, Wu LD, Liu YS, Hu B, Bi CL, Chen YF, Liu XX, Ge C, Zhang Y, Zhang M. Dickkopf-1 as a novel predictor is associated with risk stratification by GRACE risk scores for predictive value in patients with acute coronary syndrome: a retrospective research. PLoS One. 2013;8:e54731.
27. Goliasch G, Wiesbauer F, Kastl SP, Katsaros KM, Blessberger H, Maurer G, Schillinger M, Huber K, Wojta J, Speidl WS. Premature myocardial infarction is associated with low serum levels of Wnt-1. Atherosclerosis. 2012;222:251-256.
28. Register TC, Hruska KA, Divers J, Bowden DW, Palmer ND, Carr JJ, Wagenknecht LE, Hightower RC, Xu J, Smith SC, Dietzen DJ, Langefeld CD, Freedman BI. Plasma Dickkopf1 (DKK1) concentrations negatively associate with atherosclerotic calcified plaque in African-Americans with type 2 diabetes. J Clin Endocrinol Metab. 2013;98:E60-E65.
29. Szulc P, Schoppet M, Rachner TD, Chapurlat R, Hofbauer LC. Severe abdominal aortic calcification in older men is negatively associated with DKK1 serum levels: the STRAMBO study. J Clin Endocrinol Metab. 2014;99: 617-624.
30. Gaudio A, Privitera F, Pulvirenti I, Canzonieri E, Rapisarda R, Fiore CE. The relationship between inhibitors of the Wnt signalling pathway (sclerostin and Dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus. Diab Vasc Dis Res. 2014;11:48-52.
31. Askevold ET, Lars L, Aakhus S, Ranheim T, Tønnessen T, Solberg OG, Pál AUKRUST P, Ueland T. Secreted Wnt modulators in symptomatic aortic stenosis. J Am Heart Assoc. 2012;1:e002261.
32. Grant SF, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A, Stefansson H, Emilsson V, Helgadottir A, Styrkarsdottir U, Magnusson KP, Walters GB, Palsdottir E, Jonsdottir T, Gudmundsdottir T, Gylfason A, Saemundsdottir J, Wilensky RL, Reilly MP, Rader DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdottir U, Gulcher JR, Kong A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet. 2006;38:320-323.
33. Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, Prokunina-Olsson L, Ding CJ, Swift AJ, Narisu N, Hu T, Pruim R, Xiao R, Li XY, Conneely KN, Riebow NL, Sprau AG, Tong M, White PP, Hetrick KN, Barnhart MW, Bark CW, Goldstein JL, Watkins L, Xiang F, Saramies J, Buchanan TA, Watanabe RM, Valle TT, Kinnunen L, Abecasis GR, Pugh EW, Doheny KF, Bergman RN, Tuomilehto J, Collins FS, Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science. 2007;316:1341-1345.
34. Li X, Shan J, Chang W, Kim I, Bao J, Lee HJ, Zhang X, Samuel VT, Shulman GI, Liu D, Zheng J, Wu D. Chemical and genetic evidence for the involvement of Wnt antagonist Dickkopf2 in regulation of glucose metabolism. Proc Natl Acad Sci USA. 2012;109:11402-11407.